<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00614445</url>
  </required_header>
  <id_info>
    <org_study_id>DIC-301</org_study_id>
    <nct_id>NCT00614445</nct_id>
  </id_info>
  <brief_title>The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy</brief_title>
  <official_title>A Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Of The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duchesnay Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Premier Research Group plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duchesnay Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Diclectin® (doxylamine succinate USP 10 mg
      and pyridoxine HCl 10 mg) is more effective at controlling the nausea and vomiting of
      pregnancy than a placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nausea and vomiting of pregnancy (NVP), also known as &quot;morning sickness,&quot; is a common
      condition that affects a large percentage of pregnant women. The symptoms can range from mild
      nausea to severe nausea and vomiting for which a woman may need to be hospitalized. Nausea
      and vomiting of pregnancy can affect a woman's quality of life and ability to conduct daily
      activities.

      Diclectin® is a combination of 10 mg doxylamine succinate (an antihistamine), and 10 mg
      pyridoxine hydrochloride (vitamin B6) in a delayed release tablet formulation. It has been
      commercially available in Canada for the management of NVP for over 25 years and has been
      prescribed to over 33 million pregnant women.

      Presently, there is no Food Drug and Administration (FDA) approved drug on the market to
      treat the symptoms of NVP. This study will test the efficacy of Diclectin® (doxylamine 10 mg,
      pyridoxine 10 mg in a delayed-release formulation) for NVP.

      Patients enrolled in the study will receive between 2 and 4 tablets of Diclectin® or placebo
      daily, depending on their symptoms for up to 14 days. Patients will assess their symptoms of
      nausea and vomiting daily using a standardized questionnaire.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diclectin Versus Placebo for Treatment of Nausea and Vomiting of Pregnancy (NVP) as Measured by the Change in Pregnancy Unique-Quantification of Emesis (PUQE) Overall Score of Symptoms From Baseline (Day 1) to End of Study Visit (Day 15).</measure>
    <time_frame>Baseline (Day 1) to End of Study Visit Day 15 (± 1 day)</time_frame>
    <description>The objective of this double-blind, randomized, placebo-controlled study was to assess the efficacy, safety, and tolerability of oral Diclectin® in the treatment of nausea and vomiting of pregnancy (NVP) as measured by the Pregnancy Unique-Quantification of Emesis (PUQE) overall score of symptoms from baseline (Day 1) to end of study visit (Day 15). The PUQE score measured hours of nausea, number of times vomiting, and number of times retching for a TOTAL overall score of symptoms on a scale rated from 3 (no symptoms) to 15 (most severe).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">280</enrollment>
  <condition>Nausea and Vomiting of Pregnancy</condition>
  <arm_group>
    <arm_group_label>Diclectin®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diclectin® (doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg) delayed release tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets identical in size, shape, taste, and color to the experimental treatment (Diclectin®)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg</intervention_name>
    <description>up to 4 tablets daily, titrated according to the protocol</description>
    <arm_group_label>Diclectin®</arm_group_label>
    <other_name>Diclectin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 to 4 tablets daily titrated according to the protocol</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient has signed a written informed consent to participate in the study and has
             agreed to follow dosing instructions and complete all required study visits.

          -  The patient is a pregnant female age equal to or greater than 18 years old.

          -  The patient's entry ultrasound indicates a viable pregnancy and confirms gestational
             age of the fetus is 7-14 weeks at the anticipated time of the first dose of study
             medication or placebo. If an ultrasound was done within 4 weeks of the admission
             visit, and results can be obtained, an additional ultrasound is not necessary.

          -  The patient is suffering from NVP and has a Pregnancy Unique Quantification of Emesis
             (PUQE) score ≥6.

          -  The patient has not responded to conservative management consisting of
             dietary/lifestyle advice according to the 2004 ACOG Practice Bulletin.

          -  The patient agrees, if on a multivitamin, to continue on their current dose of
             multivitamin for the duration of the trial.

          -  The patient does not plan termination of the pregnancy.

        Exclusion Criteria:

          -  The investigator confirms the patient's nausea and vomiting is of etiology other than
             Nausea and Vomiting of Pregnancy (NVP).

          -  The patient has gestational trophoblastic disease or multifetal gestation.

          -  The patient has a condition for which antihistamines, in the opinion of the
             investigator, are contraindicated (epilepsy, alcoholism, glaucoma, chronic lung
             disease, urinary retention, heart block, etc.).

          -  The patient has used antihistamines, anticholinergics, dopamine antagonists, serotonin
             antagonists, ginger, or anti-emetic therapy (including acupressure, acupuncture,
             homeopathic remedies, medical hypnosis, relief bands etc) to treat NVP in the previous
             48 hours or plans to do so during the study .

          -  The patient is using drugs that have anticholinergic activity (e.g., tricyclic
             antidepressants).

          -  The patient is taking multivitamins containing more than 10 mg of vitamin B6, or plans
             to do so during the study.

          -  The patient is taking supplementary vitamin B6 in addition to any multivitamin
             preparation, or plans to do so during the study.

          -  The patient is currently drinking any amount of alcohol.

          -  The patient has any condition that might interfere with the conduct of the study.

          -  The patient is likely to be unable to comply with study procedures because of
             inadequate cognitive skills.

          -  The patient has received an investigational drug within 30 days before enrollment in
             this study or is scheduled to receive an investigational drug during the course of
             this study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liubov Gargaun, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Duchesnay Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gideon Koren, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Motherisk Program, University of Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gary Hankins, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington Hospital Center Physicians</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Naval Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magee-Womens Hospital of University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-0587</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UTMB Pasadena Clinic</name>
      <address>
        <city>Pasadena</city>
        <state>Texas</state>
        <zip>77502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UTMB Regional Maternal &amp; Child Health Program--Pearland Clinic</name>
      <address>
        <city>Pearland</city>
        <state>Texas</state>
        <zip>77581</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2008</study_first_submitted>
  <study_first_submitted_qc>January 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2008</study_first_posted>
  <results_first_submitted>August 1, 2011</results_first_submitted>
  <results_first_submitted_qc>August 4, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 5, 2011</results_first_posted>
  <last_update_submitted>August 4, 2011</last_update_submitted>
  <last_update_submitted_qc>August 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Liubov Gargaun, M.D.</name_title>
    <organization>Duchesnay, Inc.</organization>
  </responsible_party>
  <keyword>Nausea</keyword>
  <keyword>Vomiting</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Hyperemesis gravidarum</keyword>
  <keyword>Pregnancy complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Pregnancy Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyridoxine</mesh_term>
    <mesh_term>Pyridoxal</mesh_term>
    <mesh_term>Vitamin B 6</mesh_term>
    <mesh_term>Doxylamine</mesh_term>
    <mesh_term>Dicyclomine, doxylamine, pyridoxine drug combination</mesh_term>
    <mesh_term>Doxylamine succinate</mesh_term>
    <mesh_term>Dicyclomine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This is a double-blind, randomized, multicenter, placebo-controlled study in the treatment of NVP. On Day 1, all patients will receive 2 tablets of study drug at bedtime. During Days 2-14 the patients will receive 2 tablets of study drug at bedtime plus additional study drug based upon the need for control of their nausea and vomiting.</recruitment_details>
      <pre_assignment_details>The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day. After randomization, patients will return to the clinic for evaluation on Day 4 (+/-1 day) and Day 8 (+/-1 day), and will return on Day 15 (+/-1 day) for an end of study visit. The study duration is expected to be 15 days.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Diclectin®</title>
          <description>Diclectin® (doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg) delayed release tablet</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo tablets identical in size, shape, taste, and color to the experimental treatment (Diclectin®)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="140"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
                <participants group_id="P2" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Diclectin®</title>
          <description>Diclectin® (doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg) delayed release tablet</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo tablets identical in size, shape, taste, and color to the experimental treatment (Diclectin®)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="140"/>
            <count group_id="B2" value="140"/>
            <count group_id="B3" value="280"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.9" spread="6.0"/>
                    <measurement group_id="B2" value="25.0" spread="5.6"/>
                    <measurement group_id="B3" value="25.5" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Diclectin Versus Placebo for Treatment of Nausea and Vomiting of Pregnancy (NVP) as Measured by the Change in Pregnancy Unique-Quantification of Emesis (PUQE) Overall Score of Symptoms From Baseline (Day 1) to End of Study Visit (Day 15).</title>
        <description>The objective of this double-blind, randomized, placebo-controlled study was to assess the efficacy, safety, and tolerability of oral Diclectin® in the treatment of nausea and vomiting of pregnancy (NVP) as measured by the Pregnancy Unique-Quantification of Emesis (PUQE) overall score of symptoms from baseline (Day 1) to end of study visit (Day 15). The PUQE score measured hours of nausea, number of times vomiting, and number of times retching for a TOTAL overall score of symptoms on a scale rated from 3 (no symptoms) to 15 (most severe).</description>
        <time_frame>Baseline (Day 1) to End of Study Visit Day 15 (± 1 day)</time_frame>
        <population>Planned: Approximately 280 subjects (140 subjects per treatment group) were to be enrolled to achieve 200 evaluable subjects. Analyzed: 280 enrolled subjects [261 subjects in the intent-to-treat safety (ITT-S) population; 256 subjects in the intent-to-treat efficacy (ITT-E) population].</population>
        <group_list>
          <group group_id="O1">
            <title>Diclectin®</title>
            <description>Diclectin® (doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg) delayed release tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets identical in size, shape, taste, and color to the experimental treatment (Diclectin®)</description>
          </group>
        </group_list>
        <measure>
          <title>Diclectin Versus Placebo for Treatment of Nausea and Vomiting of Pregnancy (NVP) as Measured by the Change in Pregnancy Unique-Quantification of Emesis (PUQE) Overall Score of Symptoms From Baseline (Day 1) to End of Study Visit (Day 15).</title>
          <description>The objective of this double-blind, randomized, placebo-controlled study was to assess the efficacy, safety, and tolerability of oral Diclectin® in the treatment of nausea and vomiting of pregnancy (NVP) as measured by the Pregnancy Unique-Quantification of Emesis (PUQE) overall score of symptoms from baseline (Day 1) to end of study visit (Day 15). The PUQE score measured hours of nausea, number of times vomiting, and number of times retching for a TOTAL overall score of symptoms on a scale rated from 3 (no symptoms) to 15 (most severe).</description>
          <population>Planned: Approximately 280 subjects (140 subjects per treatment group) were to be enrolled to achieve 200 evaluable subjects. Analyzed: 280 enrolled subjects [261 subjects in the intent-to-treat safety (ITT-S) population; 256 subjects in the intent-to-treat efficacy (ITT-E) population].</population>
          <units>PUQE Score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.8" lower_limit="-5.26" upper_limit="-4.34"/>
                    <measurement group_id="O2" value="-3.9" lower_limit="-4.36" upper_limit="-3.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Diclectin®</title>
          <description>Diclectin® (doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg) delayed release tablet</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo tablets identical in size, shape, taste, and color to the experimental treatment (Diclectin®)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 10.0">Intra-uterine Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Premature rupture of membrane</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Foetal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adominal Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="133"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="133"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="133"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="133"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="133"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="133"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>No unpublished data given to the investigator may be transmitted to a third party without prior approval of the sponsor in writing. No publications or communications involving the results of the trial are authorized without prior review and written consent from the sponsor. The investigator must agree to send the sponsor for review prior to their submission. The sponsor reserves the right to delete from such materials any part or parts deemed to be confidential or proprietary.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Gallo</name_or_title>
      <organization>Duchesnay, Inc.</organization>
      <phone>450-433-7734</phone>
      <email>mgallo@duchesnay.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

